Become a part of the Department that touches the lives of every American! At the Department of Health and Human Services (HHS) you can give back to your community, state, and country by making a difference in the lives of Americans everywhere. It is the principal agency for protecting the health of citizens. Join HHS and help to make our world healthier, safer, and better for all Americans.
This announcement is open continuous for 90 days, or until the hiring need has been met, with the following cut-off dates for certification:
- June 5th, 2014
- July 5th, 2014
- August 4th, 2014
As a Chemist in the Office of Pharmaceutical Science (OPS), Center for Drug Evaluation and Research (CDER), Office of Medical Products and Tobacco, Food and Drug Administration (FDA), you will evaluate drug substance synthesis, drug product formulation design, or drug product manufacturing processes and associated control strategies, including analytical procedures used to ensure the safety, efficacy and quality of drugs produced by foreign and domestic producers.
This vacancy is also being announced concurrently with vacancy announcement HHS-FDA-CDER-14-DE-1113194BB under competitive procedures. Please review that announcement to see if you are eligible for consideration under competitive procedures. NOTE: Applicants must apply separately for each announcement in order to be considered.
PHS Commissioned Corps Officers interested in performing the duties of this position within the Commissioned Corps may apply online to this announcement under noncompetitive merit promotion procedures (Specialty Code 002). Candidates will be referred to (CC) personnel and not as candidates for conversion to a permanent career or career-conditional appointment.
This job opportunity announcement may be used to fill additional vacancies.
- Reviews and evaluates chemistry, formulation, manufacturing, controls, and biopharmaceutics including drug releases, technical aspects of labeling and environmental impact information submitted in various drug applications and supplements (i.e BLAs, NDAs, ANDAs, and INDs).
- Evaluates the adequacy of testing and control of container closure systems, starting and intermediate materials, reagents, and solvents.
- Establishes clinically relevant quality standards to ensure its clinical performance for approval to market and for the entire lifecycle of the drug product.
- Assesses the adequacy of pharmaceutical manufacturing; and, products usability and acceptability to the patient.
- Evaluates the adequacy of analytical methods and validation reports used during synthesis, characterization, manufacture, release and stability testing of drug substances and drug products.
- Communicates review outcomes including any identified deficiencies or issues, established policy and any further requests through oral and/or written communication.